Provenance Biopharmaceuticals is a Waltham, MA-based clinical-stage biotechnology company developing novel therapeutics for cancer and other serious, life-threatening diseases. Its lead molecule, DI-Leu16-IL2, is an immunocytokine developed using technology invented by founder, president and CEO Stephen D. Gillies, Ph.D.; that technology was previously licensed to Merck Serono. DI-Leu16-IL2 is currently in an investigator-sponsored Phase I clinical trial for non-Hodgkin’s lymphoma and other hematological cancers. To advance development, Provenance closed an $8M financing with Alopexx Enterprises and the companies formed Alopexx Oncology, LLC to manage the clinical program. Alopexx Enterprises, founded in 2011, focuses on acquiring and developing preclinical and early clinical compounds with emphasis on infectious diseases, oncology and CNS.

Total raised

$8M

Funding rounds

1

Latest round

Equity

Latest activity

Dec 2011